Home Cart Sign in  
Chemical Structure| 4449-51-8 Chemical Structure| 4449-51-8

Structure of Cyclopamine
CAS No.: 4449-51-8

Chemical Structure| 4449-51-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cyclopamine acts as a Hedgehog (Hh) pathway antagonist with an IC50 of 46 nM in the Hh cell assay, while also serving as a selective Smo inhibitor.

Synonyms: 11-Deoxojervine; Jervine; HSDB-3505

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cyclopamine

CAS No. :4449-51-8
Formula : C27H41NO2
M.W : 411.62
SMILES Code : O[C@@H]1CC2=CC[C@]3([H])[C@]([C@@]2(C)CC1)([H])CC4=C(C)[C@@]5(O[C@@]6([H])[C@@]([C@H]5C)([H])NC[C@@H](C)C6)CC[C@@]34[H]
Synonyms :
11-Deoxojervine; Jervine; HSDB-3505
MDL No. :MFCD09878269

Safety of Cyclopamine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Cyclopamine

Hedgehog

Isoform Comparison

Biological Activity

Description
Cyclopamine is an antagonist of the Hedgehog (Hh) pathway, demonstrating an IC50 of 46 nM in cell assays focused on the Hh pathway. Additionally, it selectively targets and inhibits Smo[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
786-0 cells 20 μM 5 days Inhibited cell proliferation, reduced cell count by 80% Mol Cancer. 2009 Dec 16;8:123.
786-0 cells 40 μM 5 days Inhibited cell proliferation, reduced cell count by 90% Mol Cancer. 2009 Dec 16;8:123.
hepatocytes 5 µM 24 h To assess the direct effects of Cyclopamine on hepatocyte proliferative activity, results showed that Cyclopamine significantly inhibited BrdU incorporation in hepatocytes Hepatology. 2010 May;51(5):1712-23.
mouse embryonic stem cells (mESCs) 5 µM 5 days Induction of mouse embryonic stem cells into mesodermal lineage, results showed successful differentiation of mESCs into mesodermal cells under 3D culture conditions. Sci Adv. 2017 May 12;3(5):e1602875.
PLC/PRF/5 and Huh7 cells 20 µM Cyclopamine inhibited the expression of Smo and Gli1 and the stimulatory effect of rhSCUBE1 on HCC cells. J Transl Med. 2022 Nov 8;20(1):520.
T21-iPSCs 400 ng/ml 12-14 days For glutamatergic neuron differentiation from neural stem cells Stem Cells Transl Med. 2017 Jun;6(6):1465-1476.
MATH1-GFP cells 10 µM 40 h To investigate the effect of SHH pathway blockade on the cell division modes of GNPs, results showed that cyclopamine treatment increased the number of MATH1 and DCX double-positive cells and DCX-positive cells, indicating that cyclopamine inhibited non-terminal symmetric divisions and enhanced asymmetric divisions and terminal neuronal symmetric divisions. Stem Cell Reports. 2015 Nov 10;5(5):816-828.
Human colon cancer epithelial cells 1-10 μM 48 h Cyclopamine treatment reduced cell proliferation and increased apoptosis, indicating the essential role of HH-GLI signaling in colon cancer cells. EMBO Mol Med. 2009 Sep;1(6-7):338-51.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice KA-induced neurodegeneration model Oral 30 mg/kg Twice daily for 3 days, then once daily for 5 days Inhibition of SHH/Gli signaling reduces cell proliferation in KA-induced neurodegeneration. Glia. 2014 Oct;62(10):1595-607
Mice Partial hepatectomy model Intraperitoneal injection 15 mg/kg Daily until the end of the experiment To evaluate the effects of Cyclopamine on liver regeneration, results showed that Cyclopamine significantly inhibited the proliferation of hepatocytes and ductular cells, and reduced liver regeneration mass and survival rate Hepatology. 2010 May;51(5):1712-23.
Nude mice Human renal cell carcinoma tumor model Intraperitoneal injection 0.5 mg/mouse Every 2 days for 19 days Inhibited tumor growth, completely abolished tumor growth Mol Cancer. 2009 Dec 16;8:123.
BALB/c nude mice HCC xenograft model Intraperitoneal injection 25mg/kg Once daily for two weeks Cyclopamine partially inhibited the promotion of HCC tumor progression by CAFs. J Transl Med. 2022 Nov 8;20(1):520.
Mice Math1-GFP;Dcx-DsRed;Patched+//C0 mice Intraperitoneal injection 10 mg/kg Every 3 days, from E16 to P21 To investigate the effect of SHH pathway blockade on the cell division modes of GNPs, results showed that cyclopamine treatment decreased the number of MATH1-positive cells and increased the number of DCX-positive and MATH1/DCX double-positive cells, indicating that cyclopamine reversed the shift from asymmetric to symmetric divisions. Stem Cell Reports. 2015 Nov 10;5(5):816-828.
Nude mice Human colon cancer xenograft model Intratumoral injection 10 mg/kg Twice daily, continuous treatment Cyclopamine treatment inhibited the growth of human colon cancer xenografts, indicating the critical role of HH-GLI signaling in tumor growth. EMBO Mol Med. 2009 Sep;1(6-7):338-51.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.43mL

0.49mL

0.24mL

12.15mL

2.43mL

1.21mL

24.29mL

4.86mL

2.43mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories